Profound Medical Stock Surges 20% on Strong Preliminary Q3 Results

Profound Medical's stock price jumped approximately 20% in late trading following the company's announcement of strong preliminary third-quarter 2026 financial results. The surge suggests an acceleration in the company's sales pace and significant penetration of its products into new hospitals and medical centers. Preliminary, unaudited figures indicate that total revenue for the third quarter is expected to be between $9.8 million and $10.0 million. This represents substantial growth of 85% to 89% compared to the $5.3 million in revenue reported for the third quarter of 2025. The current forecast also shows an unusually high sequential quarterly growth of nearly 300%, as second-quarter 2026 revenues were only $2.5 million.

These preliminary results significantly exceed analyst expectations, which had projected revenue of $6.78 million for the quarter. Profound Medical is thus expected to surpass forecasts by 45% to 47%, a surprise that fueled investor enthusiasm and a strong demand for the stock. Beyond revenue, the company highlighted a substantial improvement in its operating profitability, with gross profit margins expected to exceed 70% for the quarter ending September 30, 2026.

Profound Medical focuses on developing advanced medical systems for minimally invasive, targeted treatment of prostate diseases. Its flagship technology, TULSA-PRO, combines real-time MRI imaging with therapeutic ultrasound energy to precisely treat diseased tissue while minimizing damage to surrounding healthy areas, thereby reducing patient side effects. The reported revenue acceleration is attributed to the increasing adoption of this technology by physicians and hospitals.

Company management attributes the growth to two complementary channels: increased utilization of existing systems, meaning more procedures performed at centers that have already installed the equipment, and geographic and business expansion through new contracts and installations in previously untapped hospitals. The company also markets a complementary platform, Sonalleve, for treating other conditions like uterine fibroids, diversifying its revenue streams.

This growth occurs within the broader context of the oncology treatment market, which is shifting from open surgical procedures or traditional radiation therapy towards minimally invasive technologies. Patients and healthcare systems are seeking alternatives that offer faster recovery times and better preservation of physiological functions, a niche Profound Medical is targeting. The company's CEO and Chairman of the Board, Aaron Manawat, described the third quarter as a historic milestone, reflecting solid commercial momentum for its developed platforms now entering widespread application.

Wall Street investors are now awaiting the full, audited financial statements, scheduled for release on November 5, 2026, after market close. A conference call accompanying the release is expected to provide further details on projections for the fourth quarter and the full year 2027, though the company cautioned that current figures are preliminary and subject to minor adjustments.